BIO-TECHNE TO PRESENT AT THE CITI 2022 VIRTUAL HEALTHCARE CONFERENCE

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced that Jim Hippel, the Executive Vice President and CFO, will present at the Citi 2022 Virtual Healthcare Conference on February 24, 2022, at 10:15 a.m. EST. The presentation will be accessible via the company's Investor Relations website. Bio-Techne is a leading developer of purified proteins and reagent solutions, including diagnostics and genomic tools, generating approximately $931 million in net sales in fiscal 2021 with around 2,700 employees globally.

MINNEAPOLIS, Feb. 22, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Citi 2022 Virtual Healthcare Conference on Thursday, February 24, 2022, at 10:15 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx^® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $931 million in net sales in fiscal 2021 and has approximately 2,700 employees worldwide.

Contact:	David Clair, Senior Director, Investor Relations & Corporate Development
	david.clair@bio-techne.com
	612-656-4416

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-citi-2022-virtual-healthcare-conference-301487806.html

SOURCE Bio-Techne Corporation

FAQ

When will Bio-Techne present at the Citi 2022 Virtual Healthcare Conference?

Bio-Techne will present on February 24, 2022, at 10:15 a.m. EST.

Who will represent Bio-Techne at the Citi 2022 Virtual Healthcare Conference?

Jim Hippel, Executive Vice President and CFO, will represent Bio-Techne.

Where can I watch Bio-Techne's presentation at the Citi 2022 Virtual Healthcare Conference?

The presentation can be accessed via Bio-Techne's Investor Relations website.

What is Bio-Techne known for?

Bio-Techne specializes in developing purified proteins, reagent solutions, and diagnostic products.

How much revenue did Bio-Techne generate in fiscal 2021?

Bio-Techne generated approximately $931 million in net sales in fiscal 2021.